Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study

BACKGROUND: In SELECT-PsA 1, a randomised double-blind phase 3 study, upadacitinib 15 mg and 30 mg were superior to placebo and non-inferior to adalimumab in ≥20% improvement in American College of Rheumatology (ACR) criteria at 12 weeks in patients with psoriatic arthritis (PsA). Here, we report 56...

Descripción completa

Detalles Bibliográficos
Autores principales: McInnes, Iain B, Kato, Koji, Magrey, Marina, Merola, Joseph F, Kishimoto, Mitsumasa, Pacheco-Tena, César, Haaland, Derek, Chen, Liang, Duan, Yuanyuan, Zueger, Patrick, Liu, John, Lippe, Ralph, Pangan, Aileen L, Behrens, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Psoriatic Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524381/
https://www.ncbi.nlm.nih.gov/pubmed/34663636
http://dx.doi.org/10.1136/rmdopen-2021-001838

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524381/
https://www.ncbi.nlm.nih.gov/pubmed/34663636
http://dx.doi.org/10.1136/rmdopen-2021-001838

Ejemplares similares